Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases
Public ClinicalTrials.gov record NCT02967380. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Dynamic Contrast Enhanced Steady State T1-Weighted Perfusion MRI (DCE MRI): Characterization of Intracranial Lesions
Study identification
- NCT ID
- NCT02967380
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Not applicable
- Lead sponsor
- University of Southern California
- Other
- Enrollment
- 14 participants
Conditions and interventions
Conditions
- Adult Anaplastic (Malignant) Meningioma
- Adult Anaplastic Astrocytoma
- Adult Anaplastic Ependymoma
- Adult Anaplastic Oligodendroglioma
- Adult Brain Stem Glioma
- Adult Choroid Plexus Neoplasm
- Adult Diffuse Astrocytoma
- Adult Ependymoblastoma
- Adult Ependymoma
- Adult Giant Cell Glioblastoma
- Adult Glioblastoma
- Adult Gliosarcoma
- Adult Grade II Meningioma
- Adult Medulloblastoma
- Adult Mixed Glioma
- Adult Oligodendroglioma
- Adult Papillary Meningioma
- Adult Pineal Gland Astrocytoma
- Adult Pineoblastoma
- Adult Primary Melanocytic Lesion of Meninges
- Adult Supratentorial Primitive Neuroectodermal Tumor
- Malignant Adult Intracranial Hemangiopericytoma
- Metastatic Malignant Neoplasm in the Brain
- Multiple Sclerosis
- Recurrent Adult Brain Neoplasm
Interventions
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging Procedure
- Gadobenate Dimeglumine Drug
- Gadobutrol Drug
- Gadopentetate Dimeglumine Radiation
Procedure · Drug · Radiation
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 13, 2011
- Primary completion
- Oct 13, 2014
- Completion
- Oct 13, 2015
- Last update posted
- Mar 26, 2017
2011 – 2015
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| USC / Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02967380, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 26, 2017 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02967380 live on ClinicalTrials.gov.